Skip to main content
Top
Published in: International Journal of Clinical Pharmacy 4/2012

01-08-2012 | Research Article

Exploring the role of renal pharmacists in outpatient dialysis centres: a qualitative study

Authors: Teresa M. Salgado, Rebekah Moles, Shalom I. Benrimoj, Fernando Fernandez-Llimos

Published in: International Journal of Clinical Pharmacy | Issue 4/2012

Login to get access

Abstract

Background Pharmacists’ involvement in outpatient dialysis centres in Australia is currently limited, despite the positive contribution of pharmacists to renal patients’ medication management and health outcomes outlined in the literature. An expanded role for pharmacists in this setting may be required as a consequence of the increasing burden of renal disease in the population. Objective To explore renal-specialised hospital pharmacists’ intentions to implement pharmacy services in outpatient dialysis centres. Setting Australian renal-specialised hospital pharmacists. Method Semi-structured interviews were conducted with a purposeful sample of renal pharmacists recruited through the Society of Hospital Pharmacists of Australia Renal Special Interest Group. The interview guide was developed based on the theory of planned behaviour. To identify behavioural intention, the three components of the theory—attitudes, subjective norm, and perceived behavioural control—were explored. The interviews were recorded, transcribed verbatim, and thematically content analysed following a qualitative approach. Main Outcome Measures Pharmacists’ views on their potential involvement and perceived ease or difficulty in implementing pharmacy services in outpatient dialysis centres. Results Thirteen renal pharmacists were interviewed until data saturation achievement. The following services for this setting were suggested: medication reconciliation, medication review, patient education, promotion of compliance, involvement in protocol development with subsequent anaemia/phosphate management. Pharmacists demonstrated positive attitudes towards the implementation of the services. Outcomes expected included benefits to patients, the renal team, and the pharmacy profession, as well as economic savings due to dose optimisation and improvement of patients’ adherence. Subjective norm was favourable meaning that nephrologists, nurses and patients were expected to be receptive towards future pharmacy services. Barriers pointed out for the implementation comprised: funding, hospital administrators’ approval, time and staff shortage, academic training, relationship with physicians, and attitudes of pharmacists, renal team, and patients. Facilitators mentioned by respondents included: having an interview room with access to information sources, consent from the team, access to patients’ profiles, and a full-time pharmacist with a clearly defined role. Conclusion Pharmacists showed positive attitudes, favourable subjective norm and strong perceived behavioural control, which originated a clear behavioural intention to develop pharmacy services in outpatient dialysis centres. The potential barriers and enablers outlined should be taken into account, as well as the holistic approach for the successful implementation of cognitive pharmacy services.
Literature
1.
go back to reference Chisholm-Burns MA, Kim Lee J, Spivey CA, Slack M, Herrier RN, Hall-Lipsy E, et al. US pharmacists’ effect as team members on patient care: systematic review and meta-analyses. Med Care. 2010;48(10):923–33.PubMedCrossRef Chisholm-Burns MA, Kim Lee J, Spivey CA, Slack M, Herrier RN, Hall-Lipsy E, et al. US pharmacists’ effect as team members on patient care: systematic review and meta-analyses. Med Care. 2010;48(10):923–33.PubMedCrossRef
2.
go back to reference Koshman SL, Charrois TL, Simpson SH, McAlister FA, Tsuyuki RT. Pharmacist care of patients with heart failure: a systematic review of randomized trials. Arch Intern Med. 2008;168(7):687–94.PubMedCrossRef Koshman SL, Charrois TL, Simpson SH, McAlister FA, Tsuyuki RT. Pharmacist care of patients with heart failure: a systematic review of randomized trials. Arch Intern Med. 2008;168(7):687–94.PubMedCrossRef
3.
go back to reference Boudreau DM, Capoccia KL, Sullivan SD, Blough DK, Ellsworth AJ, Clark DL, et al. Collaborative care model to improve outcomes in major depression. Ann Pharmacother. 2002;36(4):585–91.PubMedCrossRef Boudreau DM, Capoccia KL, Sullivan SD, Blough DK, Ellsworth AJ, Clark DL, et al. Collaborative care model to improve outcomes in major depression. Ann Pharmacother. 2002;36(4):585–91.PubMedCrossRef
4.
go back to reference Salgado TM, Moles R, Benrimoj SI, Fernandez-Llimos F. Pharmacists’ interventions in the management of patients with chronic kidney disease: a systematic review. Nephrol Dial Transplant. 2012;27(1):276–92.PubMedCrossRef Salgado TM, Moles R, Benrimoj SI, Fernandez-Llimos F. Pharmacists’ interventions in the management of patients with chronic kidney disease: a systematic review. Nephrol Dial Transplant. 2012;27(1):276–92.PubMedCrossRef
5.
go back to reference Stemer G, Lemmens-Gruber R. Clinical pharmacy activities in chronic kidney disease and end-stage renal disease patients: a systematic literature review. BMC Nephrol. 2011;12(1):35.PubMedCrossRef Stemer G, Lemmens-Gruber R. Clinical pharmacy activities in chronic kidney disease and end-stage renal disease patients: a systematic literature review. BMC Nephrol. 2011;12(1):35.PubMedCrossRef
6.
go back to reference Pai AB, Boyd A, Depczynski J, Chavez IM, Khan N, Manley H. Reduced drug use and hospitalization rates in patients undergoing hemodialysis who received pharmaceutical care: a 2-year, randomized, controlled study. Pharmacotherapy. 2009;29(12):1433–40.PubMedCrossRef Pai AB, Boyd A, Depczynski J, Chavez IM, Khan N, Manley H. Reduced drug use and hospitalization rates in patients undergoing hemodialysis who received pharmaceutical care: a 2-year, randomized, controlled study. Pharmacotherapy. 2009;29(12):1433–40.PubMedCrossRef
7.
go back to reference Leung WY, So WY, Tong PC, Chan NN, Chan JC. Effects of structured care by a pharmacist-diabetes specialist team in patients with type 2 diabetic nephropathy. Am J Med. 2005;118(12):1414.PubMedCrossRef Leung WY, So WY, Tong PC, Chan NN, Chan JC. Effects of structured care by a pharmacist-diabetes specialist team in patients with type 2 diabetic nephropathy. Am J Med. 2005;118(12):1414.PubMedCrossRef
8.
go back to reference Yokum D, Glass G, Cheung CF, Cunningham J, Fan S, Madden AM. Evaluation of a phosphate management protocol to achieve optimum serum phosphate levels in hemodialysis patients. J Ren Nutr. 2008;18(6):521–9.PubMedCrossRef Yokum D, Glass G, Cheung CF, Cunningham J, Fan S, Madden AM. Evaluation of a phosphate management protocol to achieve optimum serum phosphate levels in hemodialysis patients. J Ren Nutr. 2008;18(6):521–9.PubMedCrossRef
9.
go back to reference Bucaloiu ID, Akers G, Bermudez MC, Mainali R, Brown BL, Roberts SS, et al. Outpatient erythropoietin administered through a protocol-driven, pharmacist-managed program may produce significant patient and economic benefits. Manag Care Interface. 2007;20(6):26–30.PubMed Bucaloiu ID, Akers G, Bermudez MC, Mainali R, Brown BL, Roberts SS, et al. Outpatient erythropoietin administered through a protocol-driven, pharmacist-managed program may produce significant patient and economic benefits. Manag Care Interface. 2007;20(6):26–30.PubMed
10.
go back to reference Roberts AS, Benrimoj SI, Chen TF, Williams KA, Aslani P. Implementing cognitive services in community pharmacy: a review of models and frameworks for change. Int J Pharm Pract. 2006;14(2):105–13.CrossRef Roberts AS, Benrimoj SI, Chen TF, Williams KA, Aslani P. Implementing cognitive services in community pharmacy: a review of models and frameworks for change. Int J Pharm Pract. 2006;14(2):105–13.CrossRef
11.
go back to reference Gastelurrutia MA, Fernandez-Llimos F, Benrimoj SI, Castrillon CC, Faus MJ. Barriers for the implementation of cognitive services in Spanish community pharmacies. Aten Primaria. 2007;39(9):465–70.PubMedCrossRef Gastelurrutia MA, Fernandez-Llimos F, Benrimoj SI, Castrillon CC, Faus MJ. Barriers for the implementation of cognitive services in Spanish community pharmacies. Aten Primaria. 2007;39(9):465–70.PubMedCrossRef
12.
go back to reference Roberts AS, Benrimoj SI, Chen TF, Williams KA, Aslani P. Implementing cognitive services in community pharmacy: a review of facilitators used in practice change. Int J Pharm Pract. 2006;14(3):163–70.CrossRef Roberts AS, Benrimoj SI, Chen TF, Williams KA, Aslani P. Implementing cognitive services in community pharmacy: a review of facilitators used in practice change. Int J Pharm Pract. 2006;14(3):163–70.CrossRef
13.
go back to reference Roberts AS, Benrimoj SI, Chen TF, Williams KA, Aslani P. Practice change in community pharmacy: quantification of facilitators. Ann Pharmacother. 2008;42(6):861–8.PubMedCrossRef Roberts AS, Benrimoj SI, Chen TF, Williams KA, Aslani P. Practice change in community pharmacy: quantification of facilitators. Ann Pharmacother. 2008;42(6):861–8.PubMedCrossRef
14.
go back to reference Rossing C, Hansen EH, Krass I. Barriers and facilitators in pharmaceutical care: perceptions and experiences among Danish community pharmacies. J Soc Admin Pharm. 2001;19(2):55–64. Rossing C, Hansen EH, Krass I. Barriers and facilitators in pharmaceutical care: perceptions and experiences among Danish community pharmacies. J Soc Admin Pharm. 2001;19(2):55–64.
15.
go back to reference Saini B, Krass I, Armour C. Specialisation in asthma: current practice and future roles. J Soc Admin Pharm. 2000;18(5):169–77. Saini B, Krass I, Armour C. Specialisation in asthma: current practice and future roles. J Soc Admin Pharm. 2000;18(5):169–77.
16.
go back to reference Farris KB, Schopflocher DP. Between intention and behavior: an application of community pharmacists’ assessment of pharmaceutical care. Soc Sci Med. 1999;49(1):55–66.PubMedCrossRef Farris KB, Schopflocher DP. Between intention and behavior: an application of community pharmacists’ assessment of pharmaceutical care. Soc Sci Med. 1999;49(1):55–66.PubMedCrossRef
17.
go back to reference Feletto E, Wilson LK, Roberts AS, Benrimoj SI. Flexibility in community pharmacy: a qualitative study of business models and cognitive services. Pharm World Sci. 2010;32(2):130–8.PubMedCrossRef Feletto E, Wilson LK, Roberts AS, Benrimoj SI. Flexibility in community pharmacy: a qualitative study of business models and cognitive services. Pharm World Sci. 2010;32(2):130–8.PubMedCrossRef
18.
go back to reference Roberts AS, Benrimoj SI, Chen TF, Williams KA, Hopp TR, Aslani P. Understanding practice change in community pharmacy: a qualitative study in Australia. Res Social Adm Pharm. 2005;1(4):546–64.PubMedCrossRef Roberts AS, Benrimoj SI, Chen TF, Williams KA, Hopp TR, Aslani P. Understanding practice change in community pharmacy: a qualitative study in Australia. Res Social Adm Pharm. 2005;1(4):546–64.PubMedCrossRef
19.
go back to reference Benrimoj SI, Feletto E, Gastelurrutia MA, Martinez Martinez F, Faus MJ. A holistic and integrated approach to implementing cognitive pharmaceutical services. Ars Pharm. 2010;51(2):69–87. Benrimoj SI, Feletto E, Gastelurrutia MA, Martinez Martinez F, Faus MJ. A holistic and integrated approach to implementing cognitive pharmaceutical services. Ars Pharm. 2010;51(2):69–87.
20.
go back to reference Ajzen I. The theory of planned behavior. Organ Behav Hum Decis Process. 1991;50:179–211.CrossRef Ajzen I. The theory of planned behavior. Organ Behav Hum Decis Process. 1991;50:179–211.CrossRef
21.
go back to reference Herbert KE, Urmie JM, Newland BA, Farris KB. Prediction of pharmacist intention to provide Medicare medication therapy management services using the theory of planned behavior. Res Social Adm Pharm. 2006;2(3):299–314.PubMedCrossRef Herbert KE, Urmie JM, Newland BA, Farris KB. Prediction of pharmacist intention to provide Medicare medication therapy management services using the theory of planned behavior. Res Social Adm Pharm. 2006;2(3):299–314.PubMedCrossRef
22.
go back to reference Perkins MB, Jensen PS, Jaccard J, Gollwitzer P, Oettingen G, Pappadopulos E, et al. Applying theory-driven approaches to understanding and modifying clinicians’ behavior: what do we know? Psychiatr Serv. 2007;58(3):342–8.PubMedCrossRef Perkins MB, Jensen PS, Jaccard J, Gollwitzer P, Oettingen G, Pappadopulos E, et al. Applying theory-driven approaches to understanding and modifying clinicians’ behavior: what do we know? Psychiatr Serv. 2007;58(3):342–8.PubMedCrossRef
23.
go back to reference Gavaza P, Brown CM, Lawson KA, Rascati KL, Wilson JP, Steinhardt M. Examination of pharmacists’ intention to report serious adverse drug events (ADEs) to the FDA using the theory of planned behavior. Res Social Adm Pharm. 2010;7(4):369–82.PubMedCrossRef Gavaza P, Brown CM, Lawson KA, Rascati KL, Wilson JP, Steinhardt M. Examination of pharmacists’ intention to report serious adverse drug events (ADEs) to the FDA using the theory of planned behavior. Res Social Adm Pharm. 2010;7(4):369–82.PubMedCrossRef
24.
go back to reference Rashidian A, Russell I. Intentions and statins prescribing: can the theory of planned behaviour explain physician behaviour in following guideline recommendations? J Eval Clin Pract. 2011;17(4):749–57.PubMedCrossRef Rashidian A, Russell I. Intentions and statins prescribing: can the theory of planned behaviour explain physician behaviour in following guideline recommendations? J Eval Clin Pract. 2011;17(4):749–57.PubMedCrossRef
25.
go back to reference Chisholm MA, Williamson GM, Lance CE, Mulloy LL. Predicting adherence to immunosuppressant therapy: a prospective analysis of the theory of planned behaviour. Nephrol Dial Transplant. 2007;22(8):2339–48.PubMedCrossRef Chisholm MA, Williamson GM, Lance CE, Mulloy LL. Predicting adherence to immunosuppressant therapy: a prospective analysis of the theory of planned behaviour. Nephrol Dial Transplant. 2007;22(8):2339–48.PubMedCrossRef
26.
go back to reference Patton MQ. Qualitative evaluation and research methods. 2nd ed. Newbury Park, CA: Sage; 1990. Patton MQ. Qualitative evaluation and research methods. 2nd ed. Newbury Park, CA: Sage; 1990.
28.
go back to reference Bowen GA. Naturalistic inquiry and the saturation concept: a research note. Qual Res. 2008;8(1):137–52.CrossRef Bowen GA. Naturalistic inquiry and the saturation concept: a research note. Qual Res. 2008;8(1):137–52.CrossRef
29.
go back to reference Whiteley AM, Whiteley J. The familiarization study in qualitative research: from theory to practice. Qual Res J. 2006;6(1):69–85.CrossRef Whiteley AM, Whiteley J. The familiarization study in qualitative research: from theory to practice. Qual Res J. 2006;6(1):69–85.CrossRef
30.
go back to reference Hsieh HF, Shannon SE. Three approaches to qualitative content analysis. Qual Health Res. 2005;15(9):1277–88.PubMedCrossRef Hsieh HF, Shannon SE. Three approaches to qualitative content analysis. Qual Health Res. 2005;15(9):1277–88.PubMedCrossRef
32.
go back to reference Manley HJ, Garvin CG, Drayer DK, Reid GM, Bender WL, Neufeld TK, et al. Medication prescribing patterns in ambulatory haemodialysis patients: comparisons of USRDS to a large not-for-profit dialysis provider. Nephrol Dial Transplant. 2004;19(7):1842–8.PubMedCrossRef Manley HJ, Garvin CG, Drayer DK, Reid GM, Bender WL, Neufeld TK, et al. Medication prescribing patterns in ambulatory haemodialysis patients: comparisons of USRDS to a large not-for-profit dialysis provider. Nephrol Dial Transplant. 2004;19(7):1842–8.PubMedCrossRef
33.
go back to reference Grabe DW, Low CL, Bailie GR, Eisele G. Evaluation of drug-related problems in an outpatient hemodialysis unit and the impact of a clinical pharmacist. Clin Nephrol. 1997;47(2):117–21.PubMed Grabe DW, Low CL, Bailie GR, Eisele G. Evaluation of drug-related problems in an outpatient hemodialysis unit and the impact of a clinical pharmacist. Clin Nephrol. 1997;47(2):117–21.PubMed
34.
go back to reference Manley HJ, Drayer DK, McClaran M, Bender W, Muther RS. Drug record discrepancies in an outpatient electronic medical record: frequency, type, and potential impact on patient care at a hemodialysis center. Pharmacotherapy. 2003;23(2):231–9.PubMedCrossRef Manley HJ, Drayer DK, McClaran M, Bender W, Muther RS. Drug record discrepancies in an outpatient electronic medical record: frequency, type, and potential impact on patient care at a hemodialysis center. Pharmacotherapy. 2003;23(2):231–9.PubMedCrossRef
35.
go back to reference Mirkov S, Ball P. Design and pilot of a medication review clinic in a dialysis centre. J Pharm Pract. 2003;33(3):199–203. Mirkov S, Ball P. Design and pilot of a medication review clinic in a dialysis centre. J Pharm Pract. 2003;33(3):199–203.
36.
go back to reference Quercia RA, Abrahams R, White CM, D’Avella J, Campbell M. Cost avoidance and clinical benefits derived from a pharmacy-managed anemia program. Hosp Pharm. 2001;36(2):169–75. Quercia RA, Abrahams R, White CM, D’Avella J, Campbell M. Cost avoidance and clinical benefits derived from a pharmacy-managed anemia program. Hosp Pharm. 2001;36(2):169–75.
37.
go back to reference Sulick JA, Pathak DS. The perceived influence of clinical pharmacy services on physician prescribing behavior: a matched-pair comparison of pharmacists and physicians. Pharmacotherapy. 1996;16(6):1133–41.PubMed Sulick JA, Pathak DS. The perceived influence of clinical pharmacy services on physician prescribing behavior: a matched-pair comparison of pharmacists and physicians. Pharmacotherapy. 1996;16(6):1133–41.PubMed
39.
go back to reference Tahaineh LM, Wazaify M, Albsoul-Younes A, Khader Y, Zaidan M. Perceptions, experiences, and expectations of physicians in hospital settings in Jordan regarding the role of the pharmacist. Res Social Adm Pharm. 2009;5(1):63–70.PubMedCrossRef Tahaineh LM, Wazaify M, Albsoul-Younes A, Khader Y, Zaidan M. Perceptions, experiences, and expectations of physicians in hospital settings in Jordan regarding the role of the pharmacist. Res Social Adm Pharm. 2009;5(1):63–70.PubMedCrossRef
40.
go back to reference McGrath SH, Snyder ME, Duenas GG, Pringle JL, Smith RB, McGivney MS. Physician perceptions of pharmacist-provided medication therapy management: qualitative analysis. J Am Pharm Assoc (2003). 2010;50(1):67–71.CrossRef McGrath SH, Snyder ME, Duenas GG, Pringle JL, Smith RB, McGivney MS. Physician perceptions of pharmacist-provided medication therapy management: qualitative analysis. J Am Pharm Assoc (2003). 2010;50(1):67–71.CrossRef
41.
go back to reference Brown CA, Bailey JH, Lee J, Garrett PK, Rudman WJ. The pharmacist-physician relationship in the detection of ambulatory medication errors. Am J Med Sci. 2006;331(1):22–4.PubMedCrossRef Brown CA, Bailey JH, Lee J, Garrett PK, Rudman WJ. The pharmacist-physician relationship in the detection of ambulatory medication errors. Am J Med Sci. 2006;331(1):22–4.PubMedCrossRef
42.
go back to reference Makowsky MJ, Schindel TJ, Rosenthal M, Campbell K, Tsuyuki RT, Madill HM. Collaboration between pharmacists, physicians and nurse practitioners: a qualitative investigation of working relationships in the inpatient medical setting. J Interprof Care. 2009;23(2):169–84.PubMedCrossRef Makowsky MJ, Schindel TJ, Rosenthal M, Campbell K, Tsuyuki RT, Madill HM. Collaboration between pharmacists, physicians and nurse practitioners: a qualitative investigation of working relationships in the inpatient medical setting. J Interprof Care. 2009;23(2):169–84.PubMedCrossRef
Metadata
Title
Exploring the role of renal pharmacists in outpatient dialysis centres: a qualitative study
Authors
Teresa M. Salgado
Rebekah Moles
Shalom I. Benrimoj
Fernando Fernandez-Llimos
Publication date
01-08-2012
Publisher
Springer Netherlands
Published in
International Journal of Clinical Pharmacy / Issue 4/2012
Print ISSN: 2210-7703
Electronic ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-012-9645-z

Other articles of this Issue 4/2012

International Journal of Clinical Pharmacy 4/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine